D. Hoenemann

发表

893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation

Yijing Ren, J. Mei, Bing Hou, 2021, Journal for ImmunoTherapy of Cancer.